Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)
Human Immunodeficiency Virus-1 (HIV-1)
About this trial
This is an interventional treatment trial for Human Immunodeficiency Virus-1 (HIV-1)
Eligibility Criteria
Inclusion Criteria:
- healthy participants
- have been a non-smoker and/or have not used nicotine or nicotine-containing products for at least approximately 3 months
Exclusion Criteria:
- is a pregnant or a nursing female
- has a history of stroke, chronic seizures or major neurological disorder
- has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
- has a history of neoplastic disease (including leukemia, lymphoma, malignant melanoma), or myeloproliferative disease
Sites / Locations
Arms of the Study
Arm 1
Experimental
Doravirine fixed sequence treatment
After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: Doravirine Type 1 dose (150 mg tablet [40% drug loaded granule]). During Period 2, participants received Treatment A: Doravirine 100 mg film coated tablet. During Period 3, participants received Treatment C: Doravirine Type 2 dose (150 mg tablet [30% drug loaded granule]). During Period 4, participants received Treatment D: Doravirine Type 3 dose (150 mg tablet [50% drug loaded granule]. During Period 5, participants received Treatment E: Doravirine Type 4 dose (100 mg tablet [30% drug loaded granule]). Each period was separated by a 14 day washout.